• Genprex signed a development and manufacturing agreement with a U.S.-based CDMO to scale up its diabetes gene therapy manufacturing.
• Work shifts the AAV-based program from research-grade output to cGMP production for IND-enabling preclinical studies.
• CDMO to supply drug product for future clinical trials as Genprex advances the candidate toward clinical evaluation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608180700PR_NEWS_USPR_____DA28043) on August 18, 2026, and is solely responsible for the information contained therein.